Stay updated on Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check3 days agoChange DetectedA site-wide funding-status notice was added and the site version updated from v3.4.0 to v3.4.1.SummaryDifference0.9%

- Check10 days agoChange DetectedUI enhancements include a Show glossary option and color-coded highlights for additions (green) and deletions (red) in the record history. The revision banner now displays Revision: v3.4.0.SummaryDifference1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page history shows a minor revision update (Revision: v3.3.4) replacing the prior version (v3.3.3) with no visible changes to study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedAdded a new revision entry: Revision: v3.3.3 to the Record History; removed the HHS Vulnerability Disclosure and the older Revision: v3.3.2 entry.SummaryDifference0.2%

- Check75 days agoChange DetectedA new revision entry v3.3.2 was added and v3.2.0 was removed in the record history. This appears to be an administrative version update rather than content changes.SummaryDifference0.1%

- Check82 days agoChange DetectedNotice banner about government funding and operating status was removed from the page. The page now presents the study history without this banner.SummaryDifference0.8%

Stay in the know with updates to Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.